Effects of Inhibition of NO-Synthesis on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls

This study has been completed.
Sponsor:
Information provided by:
Regional Hospital Holstebro
ClinicalTrials.gov Identifier:
NCT00345150
First received: June 24, 2006
Last updated: NA
Last verified: June 2006
History: No changes posted
  Purpose

The study tests the hypothesis that systemic and renal nitric oxide synthesis is changed in essential hypertension by investigating the effects of a non selective nitric oxide inhibitor on renal hemodynamics and sodium excretion in patients with essential hypertension. The results are compared with a group of healthy subjects.


Condition Intervention Phase
Hypertension
Drug: Ng-monomethyl-L-arginine (drug)
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single Blind
Official Title: Phase 1 Study of the Effects of Systemic Nitric Oxide Inhibition With Ng-Monomethyl-L-Arginine on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls

Resource links provided by NLM:


Further study details as provided by Regional Hospital Holstebro:

Estimated Enrollment: 30
Detailed Description:

The study investigates the effects of Ng-monomethyl-L-arginine (L-NMMA) on:

  1. renal hemodynamics (renal plasma flow and glomerular filtration rate)
  2. renal sodium excretion
  3. lithium clearance and fractional lithium excretion
  4. plasma levels of vasoactive hormones
  5. blood pressure and heart rate
  Eligibility

Ages Eligible for Study:   20 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Essential hypertension (blood pressure > 140/90) with no signs of secondary hypertension
  • P-creatinine < 200 µmol/L

Exclusion Criteria:

  • Anamnestic or clinical signs of heart disease, renal disease, liver disease, neoplastic disease, anemia or cerebro-vascular insult
  • Medication except antihypertensives
  • Drug or alcohol abuse
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00345150

Sponsors and Collaborators
Regional Hospital Holstebro
Investigators
Principal Investigator: Jesper N Bech, MD, Ph.D. Dept. of Medicine, Holstebro Hospital, 7500 Holstebro, Denmark
Study Chair: Erling B Pedersen, Professor Holstebro Hospital, 7500 Holstebro, Denmark
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00345150     History of Changes
Other Study ID Numbers: MED.RES.HOS.1995.01.JNB
Study First Received: June 24, 2006
Last Updated: June 24, 2006
Health Authority: Denmark: National Board of Health

Keywords provided by Regional Hospital Holstebro:
hypertension
nitric oxide
renal hemodynamics

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Omega-N-Methylarginine
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 01, 2014